Project ALS Competitors

If you’re seeking to start or advance your career with a purpose, Muscular Dystrophy Association is an employer that will enable you to thrive. The Muscular Dystrophy Association is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and related neuromuscular diseases. For over 70 years, MDA has led the way in accelerating research, advancing care, and advocating for the support of our families. Our mission is to empower the people we serve to live longer, more independent lives. #MDA #MuscularDystrophy #ALS #neuromuscuar. Apply now.

The American Academy of Neurology is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with more than 44,000 members, the AAN offers access to continuing education, essential practice tools, research grants, networking and advocacy opportunities, and more. Through public resources like Brain & Life, we make it easy for patients, caregivers, and anyone interested in brain health to access the latest information and guidance. Together with our members, the AAN is advancing what’s possible in brain disease treatment, cures, and prevention. It’s all in service of our mission to enhance member’s career fulfillment and promote brain health for all.

Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.